Posts

MapLight shares sink on mixed Phase 2 schizophrenia readout

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

Big Pharma-Backed MapLight Plots IPO to Advance Neuro Pipeline